Literature DB >> 7628985

Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans.

E W van Etten1, M Otte-Lambillion, W van Vianen, M T ten Kate, A J Bakker-Woudenberg.   

Abstract

The biodistribution of liposomal amphotericin B (L-AmB; AmBisome) and amphotericin B-desoxycholate were compared after a single injection of drug in uninfected immunocompetent mice and in leucopenic mice 6 h after inoculation with Candida albicans. Amphotericin B-desoxycholate was administered at the maximum tolerated dose (MTD) of 0.3 mg/kg whereas L-AmB was given at either 0.3 mg/kg or the MTD of 7 mg/kg. Amphotericin B (AmB) concentrations in the blood, liver, spleen, lungs and kidneys were determined by HPLC analysis at various intervals during the 48 h after administration. The biodistribution of both preparations of AmB followed similar patterns in both uninfected immunocompetent mice as well as those that were leucopenic and infected with C. albicans. Administration of L-AmB resulted in increased concentrations of drug in the blood, liver, and spleen but decreased concentrations in the kidney and lung. Hepatosplenic uptake of L-AmB was highly dose dependent with 7 mg/kg resulting in a relatively prolonged blood circulation. Blood and tissues retained high AmB concentrations after administration of L-AmB at the MTD. By using radiolabelled L-AmB, it was found that the high AmB concentrations in blood represented liposome-associated AmB and that during circulation in blood slow release of AmB occurred.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7628985     DOI: 10.1093/jac/35.4.509

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  30 in total

1.  In Vitro and In Vivo Exposure-Effect Relationship of Liposomal Amphotericin B against Aspergillus fumigatus.

Authors:  Maria Siopi; Johan W Mouton; Spyros Pournaras; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.

Authors:  D Andes; N Safdar; K Marchillo; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

3.  Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.

Authors:  Karl V Clemons; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  Administration of liposomal agents and blood clearance capacity of the mononuclear phagocyte system.

Authors:  E W van Etten; M T ten Kate; S V Snijders; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

5.  Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats.

Authors:  G W Boswell; I Bekersky; D Buell; R Hiles; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

6.  Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis.

Authors:  V Yardley; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

7.  A sensitive amphotericin B immunoassay for pharmacokinetic and distribution studies.

Authors:  S Machard; F Theodoro; H Benech; J M Grognet; E Ezan
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

8.  Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats.

Authors:  E W Van Etten; L E Stearne-Cullen; M ten Kate; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

9.  Stable phenotypic resistance of Candida species to amphotericin B conferred by preexposure to subinhibitory levels of azoles.

Authors:  J A Vazquez; M T Arganoza; D Boikov; S Yoon; J D Sobel; R A Akins
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

10.  A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model.

Authors:  Ellen K Wasan; Pavel Gershkovich; Jinying Zhao; Xiaohua Zhu; Karl Werbovetz; Richard R Tidwell; John G Clement; Sheila J Thornton; Kishor M Wasan
Journal:  PLoS Negl Trop Dis       Date:  2010-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.